Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Renodapt · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Renodapt Then Mycept Then Cellmune Then CellCept | EXPERIMENTAL | Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period. |
| Mycept Then CellCept Then Renodapt Then Cellmune | EXPERIMENTAL | Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period. |
| Cellmune Then Renodapt Then CellCept Then Mycept | EXPERIMENTAL | Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period. |
| CellCept Then Cellmune Then Mycept Then Renodapt | EXPERIMENTAL | Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period. |
| Name | Type | Description |
|---|---|---|
| Renodapt | DRUG | Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods. |
| Mycept | DRUG | Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods. |
| Cellmune | DRUG | Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods. |
| CellCept | DRUG | CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods. |
Inclusion Criteria: A body mass index (BMI) between 18 and 32 kilogram per meter square (kg/m\^2) Exclusion Criteria: * Any evidence of clinically significant allergic, renal, cardiac, bronchopulmonary, vascular, gastro-intestinal, neurological, metabolic or immunodeficiency disorders, cancer, he...
Renodapt is an investigational small molecule being developed by Roche Holding AG (RHHBY). It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers, and its therapeutic area is classified as Other.
Renodapt is being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, and the specific indication is not yet established. The drug is being evaluated for its safety and pharmacokinetics in early-stage trials.
Renodapt is being developed by Roche Holding AG, a multinational healthcare company. The company's stock is traded under the ticker symbol RHHBY. Roche is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
Renodapt is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its safety and pharmacokinetics.
Renodapt has one completed Phase 1 clinical trial, NCT02981290. This study compared the pharmacokinetics of mycophenolate mofetil metabolites from four tablet formulations in healthy participants. The trial enrolled 32 male participants in New Zealand and was controlled but not double-blinded.
Renodapt is not the same as mycophenolate mofetil. However, a clinical trial of Renodapt, NCT02981290, studied the pharmacokinetics of mycophenolate mofetil metabolites from four tablet formulations. This suggests Renodapt may be a formulation or prodrug related to mycophenolate mofetil, but the exact relationship is not specified.